Polymorphonuclear leukocytes (PMNs) bind rapidly and reversibly to endothelial cells induced to express P-selectin, a glycoprotein that mediates adhesive intercellular interactions. In addition, PMNs adherent to endothelium expressing P-selectin demonstrate an intracellular Ca2" transient, functionally up-regulateB2-integrins (CD11 /CD18 glycoproteins), become polarized in shape, and are primed for enhanced degranulation when subsequently stimulated with chemotactic factors. However, P-selectin induces none of these responses directly when used alone, when incorporated into model membranes, or when expressed by transfected cells. The absence of direct activation of the PMNs is not due to competing antiinflammatory effects of P-selectin; instead, purified P-selectin and P-selectin in membranes support agonist-stimulated PMN responses. Furthermore, tethering of PMNs to endothelial surfaces by P-selectin is required for priming to occur efficiently, as shown by experiments with blocking monoclonal antibodies. The priming event is directly mediated by the signaling molecule, plateletactivating factor (PAF), and is inhibited by blocking the PAF receptor on PMNs. Thus, P-selectin and PAF are components of an adhesion and activation cascade, but have distinct roles: P-selectin tethers and captures the PMN, whereas PAF mediates juxtacrine activation. In vivo, selectins may facilitate interaction of target cells with membrane-bound molecules that send intercellular signals, in addition to mediating rolling of leukocytes and other adhesive functions. (J. Clin. Invest. 1993. 92:559-570.)
Introduction
The selectins are novel molecules that mediate adhesive interactions among endothelium, leukocytes, and platelets ( 1-3). These interactions are required for physiologic inflammation and vascular homeostasis but, if dysregulated, contribute to inflammatory tissue injury and pathologic thrombosis (1) . The three members of the selectin family are differentially ex-pressed ( 1, 2). An integral membrane form of P-selectin is constitutively present in subcellular granules of platelets and endothelial cells and is rapidly translocated to the cell surface after agonist stimulation, where it mediates adhesive interactions with PMNs, monocytes, and some lymphocytes (1, 2) . Molecular cloning of P-selectin predicted that there is also an alternatively spliced variant, lacking the transmembrane domain, that is a soluble, secreted form (4) . E-selectin is restricted to endothelium, but is not constitutively present in resting endothelial cells; rather, it is synthesized and translocated to the plasma membrane after stimulation with certain cytokines. E-selectin, like P-selectin, mediates binding of PMNs, monocytes, and subsets of lymphocytes ( 1, 2) . L-selectin is present on PMNs, monocytes, and most lymphocytes and is rapidly shed from the surface after cellular activation. It binds to constitutive and inducible ligands on endothelial cells (1) (2) (3) .
Selectins recognize sialylated glycans that are attached to more complex structures on target cells ( 1-3). P-selectin and E-selectin bind to purified sugars, including sialyl Lewisx (SLEX) and sialyl Lewisa, to glycolipids and to glycoproteins under various in vitro conditions (2, 3, 5) . Characteristics of recognition sites for E-and P-selectin on myeloid cells have been described, and candidate structures for the ligands have been proposed (2, 3, (5) (6) (7) (8) (9) . However, the "biologically relevant natural ligand( s)" (5) on PMNs and other leukocytes remain to be identified (2, 5) . In addition to tethering one cell to another in cell-cell adhesion ( 1), binding of selectins to their ligands may activate target cells or alter their functional states in other ways. E-selectin is reported to directly activate PMNs, indicated by functional up-regulation ( 1 ) of f2-integrins (CDl 1/CD 18 glycoproteins) ( 10, 11 ) . A truncated, soluble, construct of E-selectin is a chemotaxin for PMNs ( 10) . Presumably, these responses result from binding to the same unknown ligand that mediates intercellular adhesion, raising the possibility that it transduces intracellular signals.
It is unknown if P-selectin-which has a similar structure to E-selectin, and may recognize similar ligands (6, 9) -can activate PMN functional responses. This issue is important because PMN activation, including functional upregulation of CD 11/CD 18 integrins, occurs when they bind to endothelial cells that are stimulated by thrombin or histamine to transiently express P-selectin ( 12-14; and data presented below). However, in the latter situation P-selectin is coexpressed with platelet-activating factor (PAF),' a biologically active lipid that stimulates PMNs ( 1, 14, 15) . This coordinate expression makes it difficult to determine if P-selectin directly induces activation responses at the endothelial surface. An additional complicating feature is that the putative soluble form of P-selectin (3, 16 ) is proposed to inhibit CDl 1 /CDl 8-dependent activation responses of PMNs, based on experiments in which the transmembrane form of the molecule was solubilized and presented in the fluid phase (17) (18) (19) . Although a mechanism for this effect was not defined, these observations imply that P-selectin is recognized by a signal-transducing receptor and that it may have both proinflammatory and antiinflammatory roles, depending on its presentation. Yet both the soluble and transmembrane forms appear to bind to the same ligand on PMNs ( 16; Ushiyama et al., manuscript submitted for publication). Thus, identification of the functional alterations that result when P-selectin binds to PMNs is required to understand its roles in complex inflammatory events, and may be a key to defining the biologically relevant ligand. Here we examined responses of PMNs adherent to human endothelial cells that were stimulated to express P-selectin. We then determined its ability to induce these functional alterations using P-selectin presented in purified forms or incorporated into model membranes, and by cells transfected with a cDNA for P-selectin.
Methods

Cells
Primary, confluent, human umbilical vein endothelial cell monolayers and suspensions of purified human PMNs were prepared as described (12) (13) (14) (15) . Chinese hamster ovary (CHO) cells stably transfected with a cDNA for P-selectin were prepared and maintained using standard methods (Disdier et al., manuscript in preparation).
P-selectin
The transmembrane form ofP-selectin was purified from human platelets (20, 21 ) . To examine its effects when presented to PMNs under various conditions, experiments were done with (a) PMNs incubated with P-selectin in the fluid phase in concentrations at, or below, those that appear to saturate its high-affinity binding sites ( 1-5 iug/ml, nM [21, 22] ), using conditions described earlier (14) , (b) purified P-selectin immobilized on plastic (20) , (c) P-selectin incorporated into planar phospholipid membranes.
Planar membranes were prepared using minor modifications ofthe method of Mimms et al. (23) . Egg phosphatidylcholine (Avanti Polar Lipids, Alabaster, AL) was diluted in chloroform/methanol (2:1 vol/ vol), dried under nitrogen, and then placed under a vacuum (20 p.s.i.) for 2 h. The lipid film was redissolved in 25 mM Tris-HCl in 150 mM NaCl, pH 8.0 ("Tris-saline"), containing octyl-f3-D-glucopyranoside (obtained from Calbiochem Corp., San Diego, CA) at a 15:1 molar ratio of detergent to lipid. In the standard preparations, the Tris-saline contained 10 ug/ml P-selectin, 40 ,g/ml glycophorin (as a control transmembrane protein), or no added protein. In some experiments a mAb, W6/32, was substituted for glycophorin as a control protein because it binds to a determinant (HLA class I) on PMNs, whereas glycophorin was a nonbinding control. To do this, we acylated the W6/32 with palmitic acid using described methods (24) , so that it would anchor in the membrane, before mixing with the phosphatidylcholine and detergent.
The detergent was removed by dialysis against Tris-saline for 36 h with three changes of dialysis fluid, leaving liposomes. Planar membranes were formed by fusion of liposomes on the surfaces of glass coverslips (25) . Before branes that formed were then washed three times with buffer without being exposed to an air interface. These membranes were uniform and continuous, as shown by microscopic examination of membranes formed from fluorescently labeled phosphatidylcholine (obtained from Avanti). A second indication that the membranes were continuous was that there was no enhanced adhesion ofPMNs stimulated with agonists (see below) to phospholipid membranes that did not contain protein.
In contrast, stimulated PMNs adhere to glass in an enhanced fashion (this is mediated by CDl 1 /CD.18 integrins) and would be expected to adhere to exposed areas of glass not coated with lipid if the model membranes were not continuous.
Increasing the concentration of P-selectin from 2 to 10 sg/ml Trissaline in the preparative mixture resulted in a concentration-dependent increase in binding of unstimulated PMNs to the planar membranes. This binding was specific for a P-selectin-mediated adhesive interaction (see Fig. 3 ).
Assays ofPMN adhesion andfunctional alterations ADHESION The assays for adhesion ofPMNs to endothelial monolayers stimulated with histamine, thrombin, or leukotriene C4 (LTC4), using PMNs radiolabeled with "'1In or using unlabeled PMNs and microscopy, have been described previously (12) (13) (14) (15) . We used minor modifications of the assay with radiolabeled PMNs to measure their binding to CHO cells transfected with P-selectin, to purified, immobilized P-selectin, and to P-selectin in model membranes.
In experiments in which we inhibited PMN adhesion to surfaces bearing P-selectin or to activated endothelial cells, we used the blocking mAb against P-selectin, G1, as described ( 14, 20) . S12, a mAb against P-selectin that does not block adhesion ( 14, 20) , mAbs against irrelevant proteins, or nonimmune murine IgG were used as controls. None of the control immunoglobulins have inhibitory effects under the conditions of these experiments ( 14, 20; and unpublished observations) . In experiments with endothelial cells, the monolayers were pretreated with the antibodies and the antibodies were also present in the PMN suspension during incubation ofthe PMNs on the monolayers ( 14) . In experiments with P-selectin presented by transfected cells or with purified P-selectin (immobilized or in model membranes), pretreatment alone with GI was sufficient to completely inhibit adhesion and, therefore, neither it nor the control antibodies were included in the PMN suspension.
FUNCTIONAL RESPONSES
To examine the effect of P-selectin on functional responses of PMNs, we incubated them on P-selectin-bearing surfaces (purified, or in planar membranes), with P-selectin in the fluid phase, or with P-selectin transfectants. A given activation response was evaluated with fluid phase P-selectin and with a minimum of one of the models for surface presentation. In key experiments, we evaluated the response with more than one ofthe surface presentations, since they are not equivalent (the density of P-selectin and the molecular makeup of the surrounding surface is different for P-selectin immobilized on plastic, incorporated into model membranes, and expressed on plasma membranes ofcells). In each experiment control solutions that contained diluents and additives that were exactly the same as in the P-selectin preparation were included. In parallel incubations PMNs were stimulated with one or more agonists that induced the activation response in question, including PAF, FMLP, or PMA, as a positive control. In additional experiments PMNs were first incubated for various times with P-selectin or a control preparation and then stimulated with an agonist to determine if P-selectin modified the activation response under these conditions. The specific agonist(s), concentrations, and other conditions that we used in individual experiments were chosen to give a range in the magnitude of the activation response ("weak" and "strong" agonists) so that we would have an equal chance to detect inhibition or enhancement of the response by P-selectin (for example, see legend to Fig. 3 (10) . Sheep erythrocytes that had been coated with iC3b (27) were layered over PMNs adherent to purified, immobilized P-selectin or control proteins; allowed to adhere for 30 min at room temperature; washed five times; and fixed for 15 min with 0.01 M NaHPO4, 2% glutaraldehyde, and 1% sucrose (pH 7.4). In parallel incubations, some replicates of adherent PMNs were stimulated with PAF, in various concentrations, for 5 min before addition of the iC3b-coated erythrocytes. The cells were stained with Giemsa to facilitate counting. The attachment index, which is the number of erythrocytes bound per 100 PMNs, was determined microscopically at x63 with oil immersion.
The same assay was used when the response of PMNs adherent to P-selectin in planar membranes was examined.
In a second assay ofCD 1 /CD 18 integrin activation, we examined functional up-regulation of CDl la/CD18 with mAb NKl /L-16, which identifies an activation-dependent epitope (28 (29) .
Quantitative up-regulation ofCD1 lb/CD 1 8 on PMN surfaces was analyzed by mAb binding and flow cytometry using the anti-CD 1 lb mAb, 60.1 (0.01 mg/ml), orthe anti-CD18 mAb, 60.3 (0.01 mg/ml), and conditions described above. Shedding of L-selectin was measured in parallel using binding of mAb Dreg 200.9 (0.01 mg/ml) (30) .
Oxygen radicalgeneration. Superoxide generation was measured as the fraction of cytochrome c reduction inhibited by superoxide dismutase (31 ) . PMNs ( 1.0 X 107/ml) were incubated on immobilized P-selectin or control proteins, or were incubated with fluid phase P-selectin or controls. After a 20-min incubation at 37°C, cytochrome c was added (0.1 mM final concentration), followed by superoxide dismutase (200 ALg/ml final concentration). In parallel, PMNs were treated with control buffer or an agonist (PAF, FMLP, or PMA). The PMNs were then centrifuged, and the reduced cytochrome c in the supernatant was measured by spectrophotometry (model DU-40; Beckman Instruments, Inc., Palo Alto, CA) at 550 nm. In some experiments PMNs were sequentially incubated with P-selectin or control proteins (20 min), followed by an agonist (30 min), and superoxide anion generation was measured.
Generation of biologically active lipids. LTB4 and PAF synthesis were assayed as previously described (32) .
Spreading andpolarization. Electron microscopy ( 12, 13) was performed on PMNs adherent to planar membranes containing P-selectin or glycophorin, and on membranes without incorporated protein.
After a 10-min incubation with the membranes, PMNs were fixed with Karnovsky's solution for 30 min, coated with atomic gold by vacuum evaporation, and examined with a model JSM35 scanning electron microscope (JEOL USA, Peabody, MA). In some experiments PAF was added to PMNs on membranes containing P-selectin or control membranes (1 0-min incubation), and they were fixed and their morphology was examined as above.
Results and Discussion
PMNs that adhere to endothelial cells stimulated to express P-selectin are activated and are primedfor enhanced secretion.
Endothelial cells stimulated with thrombin transiently express P-selectin and bind PMNs (14) . We assessed the adherent PMNs for evidence of activation or functional alterations. We found that PMNs that adhered to thrombin-treated endothelial cells demonstrated a rise in the concentration of free cytoplasmic Ca2+ ([Ca2+]j) (Fig. 1 ) . We also observed a CDl 1 /CD18-dependent component of adhesion ( 14, 33 ; and unpublished experiments), which requires PMN activation ( 1, 34) . Thus maximal adhesion of PMNs to endothelial cells stimulated with thrombin requires both P-selectin and CDl 1 /CD18 integrins ( 14); involvement of CD1 1 /CD 18 proteins indicates that the PMNs had become activated. Adherent PMNs also developed polarized morphology, a third index of activation ( 12, 13; and below) . This group of experiments showed that these responses, which are important in PMN migration, secretion, and other inflammatory events, can be induced by molecules expressed on the surface of stimulated endothelium.
We also found that PMNs adherent to endothelial cells stimulated with thrombin (2 U/ml for 5 or 10 min followed by washing) were "primed" for enhanced secretion ofthe primary granule enzyme, elastase, and the specific granule constituent, lactoferrin, when subsequently exposed to chemotactic factors. In five experiments PMNs first were incubated with buffer- dye Indo-1 and layered over confluent endothelial monolayers that had been grown on coverslips. The coverslips were mounted in wells of a custom spectrofluorimeter while the incubations with PMNs were done. Thrombin (2 U/ml; upper trace) or control buffer (lower trace) was added and the incubations continued for the period shown. Enhanced PMN adhesion to thrombin-stimulated endothelial cells occurs in this interval under these conditions ( 12) . Fluorescence in the Indo-I -loaded PMNs was measured at 410 and 480 AM as described (26) . The figure was traced from the original recording. In additional experiments thrombin added to Indo-l-loaded PMNs in the absence of endothelial cells did not induce a Ca2" transient, indicating that the signal for an increase in intracellular Ca2+came from the endothelial monolayers.
Inflammatory Roles ofP-Selectin 561 treated or thrombin-treated endothelial monolayers. Then we added the chemotactic peptide FMLP (0.3 uM final concentration) and measured secretion of lactoferrin after a further 10-min incubation. We found that the release of lactoferrin was significantly higher (P < 0.05) from PMNs incubated with thrombin-activated endothelial cells than from those incubated with control monolayers. This effect was even more apparent when we examined the concentration-response relationship for FMLP-stimulated lactoferrin secretion. PMNs that were stimulated while adherent to thrombin-activated endothelium were more responsive: concentrations ofFMLP that were below threshold for PMNs on control endothelial cells were effective in inducing secretion from PMNs incubated on monolayers stimulated with thrombin (Fig. 2, top) . The release of elastase was also enhanced (see below). There was no enhancement of granular secretion from PMNs adherent to thrombin-treated endothelial cells in the absence of FMLP (Fig. 2, top) . These experiments demonstrated that thrombinactivated endothelial cells prime PMNs for enhanced secretion. Priming may augment secretory responses of PMNs after they migrate to extravascular sites (35) or, alternatively, can potentiate endothelial injury by PMNs ifthey are stimulated at the luminal surface (36) .
The priming of PMNs was not restricted to endothelium activated by thrombin: in two experiments PMNs adherent to endothelial cells treated with LTC4 secreted increased concentrations of lactoferrin upon subsequent stimulation with FMLP. Adhesion of PMNs to endothelial cells activated with LTC4 (13), like adhesion to endothelium activated by thrombin ( 14) , is inhibited by antibodies to P-selectin (our unpublished observations). Both LTC4-and thrombin-activated endothelial cells primed PMNs for enhanced secretion in response to LTB4 in addition to FMLP. Therefore PMNs adherent to endothelium expressing P-selectin are primed for enhanced granular secretion, and stimulation of this enhanced secretion can be induced by inflammatory agonists ofdifferent classes. P-selectin is required, but not sufficient, for the priming response. We next explored the role of P-selectin in the priming response. mAb Gl, which identifies an epitope in the ligand recognition domain ofP-selectin (21 ), inhibited priming ofthe adherent PMNs (73% inhibition; Fig. 2, bottom) . In parallel, Gl inhibited PMN adhesion to thrombin-activated endothelial cells by 75%. This degree of inhibition of adhesion is similar to that in earlier experiments ( 14) . A in multiple experiments), indicating that it can tether PMNs to a membrane in the absence of other accessory molecules. This enhanced binding was inhibited by the anti-P-selectin mAb, G1 (Fig. 3, left) Fig. 3, right; and data not shown).
The experiments in Fig. 3 argued that P-selectin on the surface of an activated endothelial cell does not itself stimulate an increase in [Ca2+]i (Fig. 1) or prime PMNs for enhanced degranulation (Fig. 2) . To more directly ask this question, we examined CHO cells stably transfected with P-selectin for their ability to prime PMNs. We first characterized the adhesive interaction between the two cell types to verify its specificity. PMNs adhered avidly to P-selectin-transfected cells compared to wild-type CHO cells (Fig. 4) . The mean adhesion was fivefold higher to the transfected cells than to wild-type cells in multiple experiments. This adhesion required Ca2+ in the buffer, was completely inhibited by treatment of PMNs with saturating concentrations of fluid phase P-selectin, and was inhibited by the blocking mAb G 1; it was not inhibited by mAb S12 (20) , a nonblocking mAb against P-selectin, by the anti-CD 18 mAb, 60.3 (33), or by the anti-L-selectin mAb, LAM 1. 1 (40) (Fig. 4) . Each ofthese results is characteristic ofbinding of radiolabeled P-selectin to its high affinity ligand on PMNs, and ofPMN adhesion to purified, immobilized P-selectin (7, 14, 20, 21 ). Thus there was a specific, P-selectin-dependent adhesive interaction between the transfected cells and PMNs. The adhesion was also inhibited by treatment of the PMNs with chymotrypsin (threshold inhibition < 0.01 U/ 106 PMNs, complete inhibition at 0.1 U/ 1O6 PMNs; not shown). This result is consistent with other evidence that proteases cleave the ligand for P-selectin on myeloid cells (2, 9, 21, 41 ).
These experiments documented a specific, P-selectin-dependent adhesive interaction between PMNs and the transfected CHO cells. We then examined the ability of P-selectin expressed by the transfected cells to influence PMN secretory responses. There was no direct secretion of lactoferrin by PMNs incubated on the P-selectin transfectants, and no priming for enhanced lactoferrin secretion, when the adherent PMNs were stimulated with FMLP (not shown, P = 0.8). This was consistent with the data in Fig. 3 but, to explore this issue further, we also examined superoxide anion generation, because it was previously reported that endothelial cells activated by thrombin prime PMNs for enhanced 02 radical generation (42) and because priming for granular secretion and for superoxide production are tightly linked. Similar to our results with granular secretion, we found that adhesion ofPMNs to P-selectin-transfected CHO cells neither directly induced superoxide generation nor primed them for enhanced superoxide anion generation (P = 0.48 and 0.24, respectively) when they were stimulated with FMLP or PMA (Fig. 4, right) . These results again suggested that P-selectin does not act alone to prime ng/ml), and measured degranulation after a 10-min incubation. There was no direct release oflactoferrin from PMNs, and no priming for enhanced lactoferrin secretion in response to any of the agonists, on the P-selectin-coated surfaces compared to the control surfaces; similarity, there was no enhanced secretion of superoxide from PMNs adherent to immobilized P-selectin. We found the same result with PMNs adherent to P-selectin incorporated into model membranes (Fig. 5) . These experiments supported our conclusion that P-selectin does not directly prime PMNs for enhanced secretion. In additional experiments, immobilized P-selectin neither primed nor stimulated synthesis of PAF (n = 5). The experiments described above indicated that P-selectin does not (34, 35, 37, 38, 43 Fig.  4 , left, which documents that this concentration is saturating), and determined its effect on the surface adhesion molecules. There was no increase in CD1 lb/CD 18 ( Fig. 6, top) or shedding of L-selectin (not shown). A similar result, under different experimental conditions, was reported by Moore et al. (21 ) . We then asked if P-selectin alters CDl 1 /CD1 8 integrin function independent ofquantitative upregulation ( 1, 34) . To do this, we examined the ability of PMNs adherent to P-selectin to bind erythrocytes coated with iC3b, which is recognized by the CDl lb/CD18-integrin; this assay can be used even when high level adhesion to immobilized P-selectin precludes other assays of CD1 1 /CDl 8-integrin-mediated adhesiveness (10) . Adhesion of PMNs to purified, immobilized P-selectin did not enhance their binding ofiC3b-coated erythrocytes (Fig.  7) , indicating that it does not directly activate CDl lb/CD 1 8. We found a similar result when the same experiment was done (Fig. 6, bottom) . Thus, using independent assays of integrin function we found that P-selectin does not directly activate CDl la/CD 18 or CD1 lb/ * BUnF CDl 8. These results are similar to the finding that P-selectin in dependent on activation of CD 1 /CD1 8 integrins (45 ) , and :: * with our earlier findings using PMN adhesion to endothelial cells as the assay of CDI 1 /CD18 activation ( 14) . Although P-selectin did not directly induce functional upregulation of CD 1 /CD18 integrins, it supported and moderately enhanced CDl lb/CD18 integrin function when adher- 1 o4 ent neutrophils were stimulated with PAF (Fig. 7) . Since P-selectin does not quantitatively increase CDl lb/CD 1 8 on the FLUORESCENCE PMN plasma membrane (Fig. 6, top) , this implies that P-selecfPMNs incubated with saturating contin may enhance functional up-regulation of the integrin if the hase P-selectin. PMNs were incubated PMN is stimulated by an agonist. This result is consistent with aining P-selectin (5 ug/ml), or with our earlier observation of enhancement of agonist-stimulated It 370C. They were then incubated with adhesion of PMNs to unactivated endothelial cells, which is secretion. However, the results in Fig. 2 indicated that it is required for this response to occur efficiently in PMNs adherent to activated endothelial cells. This implies that the signal for priming comes from a different molecule expressed by the endothelium. The signaling factor was not released into the fluid phase, since buffer collected from thrombin-stimulated endothelial cells did not contain priming activity (not shown). This is consistent with earlier experiments ( 12) , and indicated that the molecule that induces priming is associated with the endothelial plasma membrane. PAF is coexpressed with P-selectin on endothelial cells stimulated with thrombin ( 14) and can bind to its receptor on PMNs and activate them when associated with the endothelial surface ( 15) . Therefore, we asked if blocking the PAF receptor on PMNs inhibited their priming for enhanced granular secretion when they were incubated with thrombin-stimulated endothelial monolayers, as in Fig. 2 . WEB 2086, a specific competitive antagonist for the PAF receptor on PMNs (46), blocked enhanced elastase release ( Fig. 8) , demonstrating that EC-associated PAF primes the leukocytes for enhanced secretion of primary as well as specific (Fig. 2) granule contents. In four of five experiments pretreatment of PMNs with the receptor antagonist also completely blocked priming for enhanced secretion of lactoferrin from PMNs adherent to thrombin-stimulated endothelial cells (see Fig. 2 ), and in a fifth experiment there was partial inhibition (P < 0.05 when the means were compared). In an additional experiment, blockade of the neutrophil PAF receptor completely inhibited the primed secretion of lactoferrin from PMNs adherent to endothelial. monolayers activated with LTC4.
The experiments described above, and others (14) , indicated that PAF is the signaling molecule expressed by thrombin-stimulated endothelial cells that induces functional alterations in PMNs. PAF ligates a receptor that is linked via G-pro- Fig. 2 ( 12, 14, 15, 33, 47) . Experiments indicating that PAF expressed by stimulated endothelial cells can mediate priming and induce [Ca2+] transients were also reported by others (1 1, 42) . However, the role played by P-selectin was previously unrecognized. The ability of mAb G1 to inhibit the priming effect (Fig. 2) , even though P-selectin does not directly mediate priming (Figs. 4 and 5) , indicates that tethering of PMNs to the endothelial surface by P-selectin is necessary for an optimal priming response and that it facilitates their interaction with membrane-bound PAF ( 14) . These experiments also show that inhibition of functional responses of target cells by antibodies that block tethering molecules, such as selectins, may indicate that adhesion mediated by them is required for the target cell to effectively interact with a second molecule that signals the functional event, rather than that the tethering molecule itselfdirectly induces the response. The ability of anti-E-selectin antibodies to inhibit CD1 lb/CD 18 activation and migration by PMNs adherent to cytokine-activated endothelium (10, 11, 48) may in part reflect such a mechanism, since endothelial cells stimulated with these cytokines express several signaling molecules, in addition to E-selectin (1, 49) .
To further examine the roles of P-selectin and PAF, we determined the effect of P-selectin on polarization and spreading of PMNs. PMNs allowed to settle onto planar phospholipid membranes that contained no incorporated protein remained rounded, as predicted from an earlier study showing that surface receptors are not redistributed (50) . PMNs on membranes containing glycophorin or W6/32, the control proteins, also were round. Similarly, PMNs adherent to P-selectin incorporated into membranes remained rounded and did not polarize or spread (Fig. 9 A) . This indicates that P-selectin alone does not provide a signal for shape change. We found the same result in multiple experiments in which PMNs adhered to purified, immobilized, P-selectin. In contrast, when PMNs adherent to P-selectin in model membranes were stimulated with PAF, there was dramatic polarization and spreading (Fig. 9 B) . Thus, this confirmed that surface-associated P-selectin can both tether PMNs and support their activation by PAF. Furthermore, while it is known that PAF can induce polarization of neutrophils in suspension or when they settle onto proteincoated surfaces (46) , Fig. 9 demonstrates that polarization in response to PAF can occur when they are first captured by P-selectin. This result contrasts with an earlier report indicating that purified, immobilized P-selectin inhibits spreading of PMNs stimulated with a chemotactic factor ( 18; also see below), but it is consistent with our observation that PMNs polarize on the surfaces ofendothelial cells that are induced to coexpress P-selectin and PAF ( 12, 13) . PMNs adherent to P-selectin in model membranes also undergo shape change when stimulated with PMA (45) .
Inflammatory roles ofP-selectin. There are several important conclusions from these experiments. They show that coexpression of P-selectin and PAF by endothelial cells induces functional responses of PMNs (Figs. 2 and 8 ), in addition to mediating adhesion ( 14) . A fluid-phase chemotactic factor is not required, demonstrating that responses such as priming can be initiated in a spatially specific manner at the endothelial Figure 9 . Stimulated PMNs polarize and spread while tethered by P-selectin to membrane surfaces. Planar membranes containing P-selectin and control membranes were prepared as described in Methods. PMNs were layered onto the planar membranes and, in some wells, were then stimulated with (PAF 10' M) for 10 min. The membranes and PMNs were fixed and viewed by scanning electron microscopy. (A) PMNs adherent to planar membranes with incorporated P-selectin remained round with minimal or no spreading. (B) When PMNs adherent to P-selectin in membranes were examined after stimulation with PAF, 95% of cells had undergone partial or complete shape change including elongation, spreading, or, as shown, development of well-defined lamellopodia and uropods.
surface. Antibody inhibition experiments indicated that P-selectin is involved in the priming process (Fig. 2) , but experiments with purified P-selectin and transfected cells showed that its role is to facilitate interaction with PAF (Fig. 8) , rather than to directly mediate priming (Figs. 4 and 5) . We conclude that P-selectin is essential, but not sufficient, for optimal priming under these conditions. Similarly, purified P-selectin and transfected cells gave a uniform result in assays of other functional responses and indicate that P-selectin tethers PMNs but does not directly activate them; however, it supports [Ca2+]I fluxes, CDl lb/CD 1 8 activation, and shape change induced by the signaling molecule, PAF (Figs. 3, 7, and 9 , and text), or by other agonists, such as FMLP. Using different presentations of P-selectin and a variety of different assays of function, we found that the responses of PMNs exposed to P-selectin were equivalent to those of control PMNs or, in some cases, somewhat enhanced (Figs. 3 and 7 , and data not shown). We saw no consistent evidence for inhibition of any PMN response, whether the P-selectin was presented in saturating concentrations in the fluid phase, immobilized in high density on plastic, or was incorporated into model membranes or expressed in the plasma membranes of transfected cells. This issue is important because of the earlier reports that P-selectin has inhibitory effects (16) (17) (18) (19) ; and below). The latter observations raised the possibility that a role of P-selectin is to blunt, or modulate, responses of PMNs to PAF or other juxtacrine signals at the endothelial surface, akin to its putative role as a soluble inhibitor acting in the fluid milieu ( 16-19) . Concomitant, or sequential, positive and negative signals are important regulatory mechanisms in a variety of intercellular interactions (51), lending credence to this idea. However, our experiments indicate that, instead, P-selectin in artificial surfaces and at the surfaces of endothelial cells facilitates PMN responses rather than blunting them. Thus, the coexpression of P-selectin and PAF is similar to the "adhesion and activation cascade" of costimulatory molecules that regulates degranulation of cytotoxic T lymphocytes and other responses of T cell subsets (52, 53) , but the role of P-selectin appears to be distinct: to capture and tether the PMN, allowing stimulation by the juxtacrine signaling molecule, PAF, to occur (Fig. 10) . Therefore, P-selectin has an additional function-to facilitate interaction of PMNs with other surface molecules-besides mediating rolling (45 ) and static ( 14) adhesive interactions of PMNs and endothelium.
While our experiments were aimed at defining roles of membrane-associated P-selectin, we also examined the effect ofP-selectin presented to the PMN in the fluid phase to directly address the question of whether it inhibits PMN responses under this condition (16) (17) (18) (19) . In the first series ofexperiments, PMNs were loaded with Indo-I and then treated with saturating concentrations (see above) of P-selectin, or (Fig. 11 ). This result, consistent in seven experiments, was similar to our experiments with P-selectin in model membranes (Fig. 3 ) and demonstrated that fluid-phase P-selectin does not globally inhibit signal transduction mechanisms. We also examined the effect of fluid phase presentation of P-selectin on CDl 1 /CD1 8 expression and activity. Saturating concentrations of P-selectin did not inhibit quantitative upregulation of CD1 lb/CD 1 8 when the PMNs were stimulated by FMLP (Fig. I 1) and, in parallel incubations in the same experiment, did not inhibit expression of the NKI-L16 epitope on CD1 la/CD 1 8 (not shown). We previously showed that fluid-phase P-selectin does not inhibit agonist-stimulated PMN adhesion to resting EC (14) , which is mediated by CDl la/CD 18 and CDl lb/CD 18. Therefore, P-selectin in the fluid phase inhibited neither quantitative nor functional upregulation of PMN integrins. We also found that fluid-phase P-selectin supported, rather than inhibited, superoxide generation by agonist-stimulated PMNs (n = 4; P = 0.77 when PMNs pretreated with P-selectin were compared to fibrinogen-pretreated PMNs) (Fig. 11) , granular secretion (n = 5; P = 0.25 for PMNs pretreated with P-selectin vs. fibrinogen), synthesis of PAF (n = 2), and synthesis and secretion of LTB4 (n = 1) (not shown 
